HC Wainwright & Co. Maintains Buy on Cidara Therapeutics, Lowers Price Target to $6
HC Wainwright & Co. analyst Ed Arce maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and lowers the price target from $7.5 to $6.
Recap: Cidara Therapeutics Q1 Earnings
Cidara Therapeutics (NASDAQ:CDTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering rate hike fears.
Cidara Therapeutics, Mundipharma To Present Results From Phase 3 Trial Of Its Rezafungin For Treatment Of Candidemia And/Or Invasive Candidiasis At European Congress of Clinical Microbiology and Infectious Diseases Meeting Apr. 23, 25
Cidara Therapeutics, Inc. (NASDAQ:CDTX) and Mundipharma today announced that the companies will present new clinical data and analyses of rezafungin, a novel, once-weekly echinocandin in development for the treatment of
Cidara Therapeutics Q4 EPS $(0.26) Up From $(0.49) YoY, Sales $7.22M Up From $3.73M YoY
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(0.26) per share. This is a 46.94 percent increase over losses of $(0.49) per share from the same period last year. The company reported $7.22 million in
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
Cidara Therapeutics (NASDAQ:CDTX) stock moved upwards by 14.1% to $0.91 during Thursday's after-market session. The company's market cap stands at $60.6 million.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.